IL-15 armored GPC3-CAR T cells

IL-15 armored GPC3-CAR T cells are autologous chimeric antigen receptor (CAR) T lymphocytes engineered to express a glypican-3 (GPC3)–specific CAR together with constitutively secreted interleukin-15 (IL-15) to enhance in vivo expansion, persistence, and antitumor activity against GPC3-positive solid tumors such as hepatocellular carcinoma and pediatric GPC3-expressing solid cancers.[3][7][11] The CAR typically incorporates an anti-GPC3 single-chain variable fragment linked to a 4-1BB costimulatory domain and CD3ζ signaling domain, while IL-15 transgene expression promotes T-cell survival and proliferation within the immunosuppressive tumor microenvironment, resulting in higher peak expansion, improved intratumoral accumulation, and greater response rates compared with non–IL-15–expressing GPC3-CAR T cells.[3][4][7][11] Clinical development has been led by the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children’s Hospital in phase 1 trials in adults and children with relapsed/refractory GPC3-positive solid tumors.[3][7][11][13]

Brand names

CATCH T cells

Other names

IL15-armored GPC3-CAR T cellsIL-15-armored GPC3-CAR T cellsIL 15-armored GPC3-CAR T cellsIL-15/anti-GPC3 CAR T cellsIL15 GPC3-CAR T cellsIL-15 GPC3-CAR T cellsIL 15 GPC3-CAR T cells